Your session is about to expire
← Back to Search
MT-3921 for Spinal Cord Injury
Study Summary
This trial is testing a new drug to see if it is effective and safe for people with a specific type of spinal cord injury.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any injuries that would affect my participation in the study's required tests.I have hereditary fructose intolerance.My spinal cord is completely severed.You have a problem with using drugs that affect your mind.I have a cervical spinal cord injury classified as AIS A, B, or C, with specific motor activity and BMI restrictions.I have a penetrating injury to my spinal cord.I am currently pregnant or breastfeeding.I have a cervical spinal cord injury classified as AIS A, B, or C, with specific motor activity and BMI <40.I have had a severe injury with an ISS score over 25.I have a cervical spinal cord injury.My spinal injury is classified as AIS A, B, or C.Your body mass index (BMI) is less than 40.I have had cancer within the last 3 years.I currently have COVID-19.My upper body strength score is 28 or less.My spinal cord injury is between my neck and mid-back, with some arm movement.
- Group 1: Placebo
- Group 2: MT-3921
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA granted authorization to MT-3921?
"The safety of MT-3921 was appraised as a 2, since this is only at the Phase 2 stage; while there are some data affirming its security, none can attest to its efficacy."
Does this research endeavor have an age limitation for potential participants?
"This clinical trial is seeking participants aged 18 or over, but no older than 75."
What is the scope of the patient sample for this research?
"This trial requires 72 participants, as defined by its inclusion criteria. The sponsor, Mitsubishi Tanabe Pharma Development America Inc., is running the medical experiment from two locations: Medical College of Wisconsin - Froedtert Hospital in Milwaukee and Stanford University in California."
How prevalent is this experimental protocol throughout the state?
"Currently, 69 sites are enrolling patients across the United States, from Milwaukee and Stanford to Houston. To reduce travel expenses associated with participating in this clinical trial, it is essential that individuals select a location nearest them."
Is enrollment currently open for this research trial?
"According to clinicaltrials.gov, this medical inquiry is actively seeking patients who meet the criteria. It was initially posted on August 27th 2021 and last updated November 14th 2022."
Who is eligible to partake in this medical research?
"This clinical research is open to individuals aged between 18 and 75 who have wounds. 72 participants are anticipated for the duration of this trial."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger